Single Probiotic versus Multiple Probiotics - A Debate On Current Scenario for Alleviating Health Benefits

Korada, Siva Kumar; Yarla, Nagendra Sastry; Mishra, Vijayendra; Abdel-Daim, Mohamed M.; Sharma, Bechan; Ashraf, Ghulam Md; Reggi, R; Palmery, Maura; Peluso, Ilaria; Kamal, Mohammad Amjad

doi:10.2174/1381612824666181012124136

Cited by 16 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several multistrain probiotics are being used for human health, animal feed and aquaculture (Markowiak and Śliżewska, 2018;Sniffen et al, 2018). However, major issues remain unresolved; whether single strains or multistrain mixtures are considered more benefi cial and whether strains in a mixture are compatible with each other (Korada et al, 2018;Ouwehand et al, 2018). The present study will describe the research fi ndings on the evolution of PGPM mixtures and the compatibility issue among their components in order to provide valuable knowledge for the development of eff ective microbial mixtures for sustainable agricultural applications.…”

Section: Introductionmentioning

confidence: 99%

Multistrain versus single-strain plant growth promoting microbial inoculants - The compatibility issue

Thomloudi

Tsalgatidou

Douka

et al. 2019

Hellenic Plant Protection Journal

View full text Add to dashboard Cite

Summary Plant Growth Promoting Microorganisms or Plant Probiotics (PGPMs) constitute a promising solution for agricultural sustainability. The concept that inoculation of PGPM mixtures may perform better in enhancing agricultural production than single strain application dates back to the discovery of plant growth rhizobacteria (PGPR) and is gaining ground in our days. This shift is highlighted by the increasing number of research publications dealing with the positive impact of microbial mixtures in promoting plant growth, controlling plant pathogens, as well as providing abiotic stress tolerance. The continuous deposition of patents as well as commercially available formulations concerning bioprotective and/or biostimulant multistrain mixtures also underlines this shift. A major issue in engineering an effective and consistent synthetic multistrain mixture appears to be the compatibility of its components. The present review provides a thorough literature survey supporting the view that treatment of plants with compatible multistrain mixtures generally exerts a better effect in plant growth and health than single-strain inoculation. Our study focuses on multistrain mixtures based on Pseudomonas, Bacillus and beneficial fungal strains, while commercial products are also being referred.

show abstract

Section: Introductionmentioning

confidence: 99%

Multistrain versus single-strain plant growth promoting microbial inoculants - The compatibility issue

Thomloudi

Tsalgatidou

Douka

et al. 2019

Hellenic Plant Protection Journal

View full text Add to dashboard Cite

show abstract

“…However, there is currently no evidence to support any assumptions of superiority of multiple strains over single‐strain probiotics 24 . Conversely, no evidence shows inferiority of multistrain probiotics over single‐strain products and/or antagonistic activity between strains in a preparation 23,24 . Further research is needed in this area before conclusive recommendations can be made over the benefits of either preparation.…”

Section: Resultsmentioning

confidence: 99%

“…An increasing tendency has been observed for commercial products to have multiple strains of microorganism, particularly products with a high number of different strains 23 . The rationale behind this is that more strains imply a broader spectrum of efficacy and, potentially, additive or synergistic effects of the strains 23 . However, there is currently no evidence to support any assumptions of superiority of multiple strains over single‐strain probiotics 24 .…”

Section: Resultsmentioning

confidence: 99%

“…24 Conversely, no evidence shows inferiority of multistrain probiotics over single-strain products and/or antagonistic activity between strains in a preparation. 23,24 Further research is needed in this area before conclusive recommendations can be made over the benefits of either preparation. As emphasized earlier, the selection of any probiotic products should be guided by convincing strain-specific evidence for the health claim made.…”

Section: Statementmentioning

confidence: 99%

See 1 more Smart Citation

Use of probiotics in clinical practice with special reference to diarrheal diseases: A position statement of the Malaysian Society of Gastroenterology and Hepatology

et al. 2020

View full text Add to dashboard Cite

Probiotics comprise a large group of microorganisms, which have different properties and thus confer different benefits. The use of probiotics has shown promising results in the management of diarrheal diseases. While the availability of probiotic products has flourished in the marketplace, there is limited guidance on the selection of probiotics for clinical use. This position paper is aimed at informing clinicians about the proper selection criteria of probiotics based on current evidence on strain-specific efficacy and safety for the management of diarrheal diseases. Members of the working group discussed issues on probiotic use in clinical practice, which were then drafted into statements. Literature to support or refute the statements were gathered through a search of medical literature from 2011 to 2020. Recommendations were formulated based on the drafted statements and evidence gathered, revised as necessary, and finalized upon agreement of all members. Twelve statements and recommendations were developed covering the areas of quality control in the manufacturing of probiotics, criteria for selection of probiotics, and established evidence for use of probiotics in diarrheal diseases in adults and children. Recommendations for the use of specific probiotic strains in clinical practice were categorized as proven and probable efficacy based on strength of evidence. Robust evidence is available to support the use of probiotics for diarrheal diseases in clinical practice. Based on the results obtained, we strongly advocate the careful evaluation of products, including manufacturing practices, strain-specific evidence, and contraindications for at-risk populations when choosing probiotics for use in clinical practice. imbalance may occur due to several factors, including diet, infection, disease (e.g. irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), type 1 and 2 diabetes, atopic eczema, and obesity), and drugs (e.g. antibiotics). 1,2 Probiotics and prebiotics are among the most well-established interventions in modulating the gut microbiota for health benefits. 1 Specifically, probiotics are

show abstract

“…Currently, also the probiotics have entered IBD therapy intending to modulate the composition of the intestinal microbiota and the response of the host’s immune system [ 8 ]. Although the mechanisms of action of probiotics are not yet fully understood, many formulations of single strains or combinations of multiple strains are commercially available [ 9 ]. The results of clinical trials evaluating the use of probiotics in IBD patients, however, have documented that although probiotics are generally safe, they are only moderately or not effective in treating IBD [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation

et al. 2020

View full text Add to dashboard Cite

Dysbiosis is commonly detected in patients with inflammatory bowel disease (IBD), supporting the concept that a dysregulated immune reaction to bacterial antigens has a pathogenic role in the development of intestinal inflammation. In the present study, we have investigated the beneficial effects of a novel probiotic formulation assembled by combining four probiotics (Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium breve, Bifidobacterium animalis subsp. Lactis) with Bacillus subtilis, a Gram-positive bacterium, with extensive bio-applications. Mice rendered colitic by administration of TNBS or DSS were administered with Bacillus subtilis alone, Vivomixx® or the novel Five strains formulation. Vivomixx® attenuated the severity of inflammation and reduced the development of signs and symptoms of colitis in both models. Adding Bacillus subtilis to Vivomixx® improved the beneficial effects of the bacterial therapy. The novel Five strains formulation was as effective as Vivomixx® in reducing the development of signs and symptoms of colitis and reduced the expression of pro-inflammatory mediators including Il-6 and Tnf-α while increased the expression of Il-10 mRNA and the number of Treg. In summary, we have shown that a novel Five strains probiotics formulation exerts beneficial effects on two chemical models of colitis, establishing Bacillus subtilis as a probiotic in rodent models of inflammation.

show abstract

Single Probiotic versus Multiple Probiotics - A Debate On Current Scenario for Alleviating Health Benefits

Cited by 16 publications

References 0 publications

Multistrain versus single-strain plant growth promoting microbial inoculants - The compatibility issue

Multistrain versus single-strain plant growth promoting microbial inoculants - The compatibility issue

Use of probiotics in clinical practice with special reference to diarrheal diseases: A position statement of the Malaysian Society of Gastroenterology and Hepatology

Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation

Contact Info

Product

Resources

About